These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1723740)

  • 1. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal.
    Baumgartner JD
    Infect Dis Clin North Am; 1991 Dec; 5(4):915-27. PubMed ID: 1723740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
    Fink MP
    Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
    Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production, characterization and biological effects of monoclonal antibodies to different parts of the gram-negative lipopolysaccharide core region.
    Appelmelk BJ; Verweij-van Vught M; Brade H; Maaskant J; Schouten W; Thijs B; MacLaren D
    Prog Clin Biol Res; 1988; 272():373-82. PubMed ID: 2455918
    [No Abstract]   [Full Text] [Related]  

  • 7. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis.
    Klaerner HG; Dahlberg PS; Acton RD; Battafarano RJ; Uknis ME; Johnston JW; Dunn DL
    J Surg Res; 1997 May; 69(2):249-54. PubMed ID: 9224390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.
    Mitov IG; Terziiski DG
    Infection; 1991; 19(6):383-90. PubMed ID: 1816107
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunotherapy of endotoxemia and septicemia.
    Baumgartner JD; Glauser MP
    Immunobiology; 1993 Apr; 187(3-5):464-77. PubMed ID: 8330909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and characterisation of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli.
    Appelmelk BJ; Verweij-van Vught AM; Maaskant JJ; Schouten WF; De Jonge AJ; Thijs LG; Maclaren DM
    J Med Microbiol; 1988 Jun; 26(2):107-14. PubMed ID: 2455054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possibilities of immunoprophylaxis and immunotherapy in gut-derived infectious-toxic shock (GITS).
    Imbach P; Hässig A; Cottier H
    Curr Stud Hematol Blood Transfus; 1992; (59):301-23. PubMed ID: 1572217
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria.
    Palliyil S; Broadbent ID
    Curr Opin Pharmacol; 2009 Oct; 9(5):566-70. PubMed ID: 19726227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Generation and characterization of avian vitelline antibodies against lipopolysaccharide and lipid A. 1. Induction and preparation of specific egg yolk antibodies (IgY) against endotoxins].
    Sasse M; Krüger M; Schade R; Hlinak A
    Berl Munch Tierarztl Wochenschr; 1998 Apr; 111(4):121-6. PubMed ID: 9581345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoprotective murine monoclonal antibodies specific for the outer-core polysaccharide and for the O-antigen of Escherichia coli 0111:B4 lipopolysaccharide (LPS).
    Coughlin RT; Bogard WC
    J Immunol; 1987 Jul; 139(2):557-61. PubMed ID: 3298431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-lipopolysaccharide antibodies in gram-negative bacteremia.
    Baumgartner JD
    Behring Inst Mitt; 1991 Feb; (88):216-21. PubMed ID: 2049041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Generation and characterization of avian vitelline antibodies against lipopolysaccharide and lipid A. 2. Investigations of specificity of egg yolk antibodies (IgY) against endotoxin].
    Sasse M; Hlinak A
    Berl Munch Tierarztl Wochenschr; 1998 Apr; 111(4):127-33. PubMed ID: 9581346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of hybridoma immunoglobulin switch variants in the analysis of the protective properties of anti-lipopolysaccharide antibodies in Escherichia coli K1 infection.
    Pelkonen S; Pluschke G
    Immunology; 1989 Oct; 68(2):260-4. PubMed ID: 2680911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies that recognize epitopes in the core and lipid A region of lipopolysaccharides.
    Pollack M; Chia JK; Koles NL; Miller M; Guelde G
    Prog Clin Biol Res; 1988; 272():327-38. PubMed ID: 2455917
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy of gram-negative septicemia.
    van Deventer SJ
    Prog Clin Biol Res; 1991; 367():135-9. PubMed ID: 1924423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.